1. Home
  2. ACET vs SERA Comparison

ACET vs SERA Comparison

Compare ACET & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACET
  • SERA
  • Stock Information
  • Founded
  • ACET 1947
  • SERA 2008
  • Country
  • ACET United States
  • SERA United States
  • Employees
  • ACET N/A
  • SERA N/A
  • Industry
  • ACET Biotechnology: Pharmaceutical Preparations
  • SERA Precision Instruments
  • Sector
  • ACET Health Care
  • SERA Health Care
  • Exchange
  • ACET Nasdaq
  • SERA Nasdaq
  • Market Cap
  • ACET 63.8M
  • SERA 70.4M
  • IPO Year
  • ACET N/A
  • SERA 2021
  • Fundamental
  • Price
  • ACET $0.62
  • SERA $2.48
  • Analyst Decision
  • ACET Strong Buy
  • SERA
  • Analyst Count
  • ACET 7
  • SERA 0
  • Target Price
  • ACET $5.60
  • SERA N/A
  • AVG Volume (30 Days)
  • ACET 371.7K
  • SERA 97.7K
  • Earning Date
  • ACET 08-07-2025
  • SERA 08-06-2025
  • Dividend Yield
  • ACET N/A
  • SERA N/A
  • EPS Growth
  • ACET N/A
  • SERA N/A
  • EPS
  • ACET N/A
  • SERA N/A
  • Revenue
  • ACET N/A
  • SERA $108,000.00
  • Revenue This Year
  • ACET N/A
  • SERA $390.13
  • Revenue Next Year
  • ACET N/A
  • SERA $440.54
  • P/E Ratio
  • ACET N/A
  • SERA N/A
  • Revenue Growth
  • ACET N/A
  • SERA 0.94
  • 52 Week Low
  • ACET $0.45
  • SERA $1.37
  • 52 Week High
  • ACET $1.64
  • SERA $9.13
  • Technical
  • Relative Strength Index (RSI)
  • ACET 36.75
  • SERA 44.34
  • Support Level
  • ACET $0.66
  • SERA $2.41
  • Resistance Level
  • ACET $0.73
  • SERA $2.79
  • Average True Range (ATR)
  • ACET 0.05
  • SERA 0.24
  • MACD
  • ACET -0.01
  • SERA -0.08
  • Stochastic Oscillator
  • ACET 0.00
  • SERA 21.50

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Share on Social Networks: